Pipeline
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Pipeline
CeliVax Core Technology
| Pipeline | Antigen Gene | Basic research | Preclinical Trial | Clinical Trial Stage | ||
|---|---|---|---|---|---|---|
| Phase-I Clinical Trial | Phase-II Clinical Trial | Phase-III Clinical Trial | ||||
| BVAC-C | HPV E6/E7 Recombination Gene |
NCT Identifier : NCT02866006
NCT Identifier : NCT02866006
NCT Identifier :
|
||||
| BVAC-B | HER2/neu Recombination Gene |
NCT Identifier : NCT03425773
|
||||
| BVAC-P | PAP / PSMA Fusion Recombination Gene |
|
||||
| BVAC-M | GP100 / MAGE-A3 Fusion Recombination Gene |
|
||||
| BVAC-Neo | Neo-Antigen |
|
||||
BVAC-C
BVAC-C uses HPV type 16/18’s carcinogen gene, E6/E7’s recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection.
CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.
Also, we are preparing for phase-II clinical trial to check co-administration effect with other medicines.
Publication
Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma : Safety, Clinical Activity, and Immunologic correlates
Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.
10.3390/jcm9010147
BVAC-B
BVAC-B uses recombination gene of human epidermal growth factor receptor 2 (Her2/neu) and applied on stomach cancer, breast cancer, and ovarian cancer.
BVAC-B completed phase-I clinical trial to check safety and drug tolerance and we are preparing for phase-II clinical trial.
BVAC-P
BVAC-P uses fusion cancer antigen of prostate acid phosphatase (PAP) and prostate-specific membrane antigen (PSMA) as antigen and applied on prostate cancer, renal cell cancer, and glioblastoma.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.
BVAC-M
BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.
BVAC-Neo
BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.
-
BVAC-C
HPV E6/E7 Recombination Gene
Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial NCT Identifier : NCT02866006
- Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
- Clinical Trial Stage : Phase-I Clinical Trial
- Clinical Trial Purpose : Check on safety, drug-tolerance, maximum tolerance dose, and preliminary validation of BVAC-C
- Clinical Trial Result : All dosages used during clinical trial were proven to be safe.
NCT Identifier : NCT02866006
- Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
- Clinical Trial Stage : Phase-II Clinical Trial
- Clinical Trial Purpose : Purpose of Clinical trial : To verify validity, safety, and tolerance either in single administration of BVAC or in joint administration of BVAC-C and chemotherapy.
- Clinical Trial Result : In progress
NCT Identifier :
- Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
- Clinical Trial Stage : Phase-II Clinical Trial
- Clinical Trial Purpose : Verification of validity, safety, and tolerance when administering BVAC-C with Immunosuppressants jointly.
- Clinical Trial Result : To be scheduled
BVAC-C
BVAC-C uses HPV type 16/18’s carcinogen gene, E6/E7’s recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection.
CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.
Also, we are preparing for phase-II clinical trial to check co-administration effect with other medicines.Publication
Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma : Safety, Clinical Activity, and Immunologic correlates
Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.
10.3390/jcm9010147 -
BVAC-B
HER2/neu Recombination Gene
Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial NCT Identifier : NCT03425773
- Indication : HER2/neu positive/recurrent gastric cancer
- Clinical Trial Stage : Phase-I Clinical Trial
- Clinical Trial Purpose : Check on safety, drug-tolerance, maximum tolerance dose, and preliminary validation of BVAC-B
- Clinical Trial Result : All dosages used during clinical trial were proven to be safe.
BVAC-B
BVAC-B uses recombination gene of human epidermal growth factor receptor 2 (Her2/neu) and applied on stomach cancer, breast cancer, and ovarian cancer.
BVAC-B completed phase-I clinical trial to check safety and drug tolerance and we are preparing for phase-II clinical trial. -
BVAC-P
PAP / PSMA Fusion Recombination Gene
Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial BVAC-P
BVAC-B uses recombination gene of human epidermal growth factor receptor 2 (Her2/neu) and applied on stomach cancer, breast cancer, and ovarian cancer.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial. -
BVAC-M
GP100 / MAGE-A3 Fusion Recombination Gene
Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial BVAC-M
BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial. -
BVAC-Neo
Neo-Antigen
Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial BVAC-Neo
BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.
